about
Therapeutic procedures in liver metastases: Conventional and future measuresHepatocellular Carcinoma: The Role of Interventional OncologySafety considerations for IGRT: Executive summary.Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control.Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.Lack of influence of intravenous contrast on head and neck IMRT dose distributions.Phase I study of individualized stereotactic body radiotherapy of liver metastases.A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosisA final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovariaEvolving perspectives in contralateral breast cancer.Point-of-care outcome assessment in the cancer clinic: audit of data quality.Re-irradiation of head and neck tumors. Benefits and toxicities.Dose escalated liver stereotactic body radiation therapy at the mean respiratory position.Radiation therapy for liver tumors: ready for inclusion in guidelines?Radiation dose-volume effects in the stomach and small bowel.Partial irradiation of the liver.Effect of breathing motion on radiotherapy dose accumulation in the abdomen using deformable registrationDeintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.Radiation therapy for hepatocellular carcinoma: from palliation to cure.Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities.Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus.Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus: radiation therapy oncology group consensus guidelines.Radiation-associated liver injury.Conformal chemoradiation for primary and metastatic liver malignancies.The role of radiotherapy in the treatment of liver metastases.Dosimetric analysis of radiation-induced gastric bleedingPartial volume tolerance of the liver to radiation.Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients.Predictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy.Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.Advances in image-guided radiation therapy.Cancer of the gallbladder and extrahepatic bile ducts.Neoadjuvant treatment for pancreatic cancer--a review.Role of palliative radiotherapy in the management of mural cardiac metastases: who, when and how to treat? A case series of 10 patientsRadiotherapy for hepatocellular carcinoma: an overview.The evolving role of radiation therapy in hepatocellular carcinoma.Conformal radiotherapy for hepatocellular carcinoma.Options for radiotherapy in the treatment of liver metastases.
P50
Q26998692-7C0F9ABB-09EC-47D5-9F0D-3E9F0449AD7DQ28071444-1BCEE053-4D7B-4CEF-9F4C-42BF7D6740EAQ30554681-05824F69-FCBE-4210-B490-6A8B58A7E6EAQ30786347-920028F6-118B-42F5-8F00-C1382E2ACBFBQ31826690-31113A31-A560-427E-B861-26A865F3BC1CQ33302524-EA184C9E-B3D4-403E-8EC8-69ED32ED89E3Q33383521-49C6C0BD-94D3-45B0-8974-914DC4489561Q33408075-B3DF7A8B-ED8D-404C-BDE4-59E464638E0CQ33418461-274C26FE-F328-4200-AD3E-E470AD256E7EQ33438615-C502795A-A36B-4F8B-B7D5-AE57F068572AQ33539675-47D93DA2-E7F8-44F5-924C-4FA59F77D155Q33548951-C7CFAC8D-2886-42B0-BF79-E61FC94EAC59Q33737047-BD307E35-9732-4908-9FAE-D67BAB7169F2Q33929462-2B150E17-A791-4C6A-921E-B1F3D9F4478CQ34005194-2E56B5D7-65F9-46C1-893F-57C23E4A29FDQ34099794-CE8F3293-4363-4A18-BBB6-A7E302E761A3Q34304933-E490302B-22EA-4555-A7CE-F727EAB42A32Q34441982-D6E53005-75C1-4EA5-B24F-AA4868679593Q34538489-57BA99FD-5581-4D2F-81F4-79290B47B38BQ34565716-9DF3EC4A-456B-420E-AF1C-21D36DE47738Q34646117-51B150BF-DD34-481E-BFAE-30C98C9DD25FQ34845036-D65AA7CD-F138-4EB1-89FD-3CF6400E522DQ34845074-A8254DCA-22EF-44A0-9537-EDC4220A737DQ35297759-59F899F5-8408-4E09-9143-3CBD584E7253Q35597404-99EC3D34-3290-44A3-9457-14E1619841D0Q35766161-2E45BADB-6B42-4756-9227-78BA81549A4DQ36177088-570701C6-066F-40B9-841C-6CD4A34D2AA9Q36267553-F9E4B61F-5C55-4C80-AA76-C1DFCB79CC7AQ36282434-DCAE07B7-01A9-412C-8CB9-C102843165E1Q36500564-D9502303-2AB5-4F8B-819A-70F88BE1E7C9Q36574645-BE3DF1FC-DF3F-448E-82E8-7B7B4CF9BA50Q36581449-9732751C-B540-45CA-8F2F-D6708F283D3EQ36756955-38FE3D68-1CAC-4C65-862A-6E18953C771BQ36908142-D6036993-C237-416B-960E-92EA8B457B6FQ37026354-6C182F00-F612-4C4F-B3D7-7C11CC922091Q37045496-7618200C-D122-4641-B792-1DD96728F213Q37072524-68042B59-8092-4557-9DF3-E4E7174200A8Q37090800-1CF7A65A-F7B1-4D15-806D-CEB11506A85CQ37097558-64388426-DD18-4672-A81E-62AED120A54AQ37305042-5878C20A-E20E-4B84-BB2B-9F5FF1FC797F
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laura A. Dawson
@ast
Laura A. Dawson
@en
Laura A. Dawson
@es
Laura A. Dawson
@nl
Laura A. Dawson
@sl
لورا أ. داوسون
@ar
type
label
Laura A. Dawson
@ast
Laura A. Dawson
@en
Laura A. Dawson
@es
Laura A. Dawson
@nl
Laura A. Dawson
@sl
لورا أ. داوسون
@ar
prefLabel
Laura A. Dawson
@ast
Laura A. Dawson
@en
Laura A. Dawson
@es
Laura A. Dawson
@nl
Laura A. Dawson
@sl
لورا أ. داوسون
@ar
P106
P1153
25652730800
P21
P31
P496
0000-0002-9068-6872